0 followers
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being eva... Read more
Andrew Cheng
Ultima Genomics
3 followers
Capricor Therapeutics
1 follower
Bloomberg Philanthropies
4 followers
Financial Finesse
2 followers
OceanX
5 followers
Cellares
2 followers
Solugen
2 followers
Thermo Fisher Scientific
174 followers
Gilead Sciences
135 followers
Biogen
121 followers
Vertex Pharmaceuticals
65 followers
Explore companies